Table 2 Treatment-emergent adverse events occurring in ≥20% of patients receiving elranatamab
From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Treatment-emergent adverse events, n (%) | n = 123 | |
|---|---|---|
Any grade | Grade 3 or 4 | |
Any treatment-emergent adverse event | 123 (100) | 87 (70.7) |
Hematologica | ||
Anemia | 60 (48.8) | 46 (37.4) |
Neutropenia | 60 (48.8) | 60 (48.8) |
Thrombocytopenia | 38 (30.9) | 29 (23.6) |
Lymphopenia | 33 (26.8) | 31 (25.2) |
Nonhematologic | ||
Cytokine release syndrome | 71 (57.7) | 0 |
Diarrhea | 52 (42.3) | 2 (1.6) |
Fatigue | 45 (36.6) | 4 (3.3) |
Decreased appetite | 41 (33.3) | 1 (0.8) |
Pyrexia | 37 (30.1) | 5 (4.1) |
COVID-19 relatedb | 36 (29.3)c | 19 (15.4) |
Injection site reaction | 33 (26.8) | 0 |
Nausea | 33 (26.8) | 0 |
Hypokalemia | 32 (26.0) | 13 (10.6) |
Cough | 31 (25.2) | 0 |
Headache | 29 (23.6) | 0 |
